Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 7/20 | 0.49 |
| ▸ | APP | P05067 | 6/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.48 |
| ▸ | TCF7L2 | Q9NQB0 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2257505 | 0.89 | APP (0.54) | SMN1; SMN2LMNATSHRCYP1A2CYP3A4 | |
| SCHEMBL2257676 | 0.80 | CTNNB1 (0.54) | SMN1; SMN2ACHEAPPCTNNB1TCF7L2 | |
| SCHEMBL3977315 | 0.79 | RAD52 (0.71) | SMN1; SMN2LMNATSHRACHEAPP | |
| SCHEMBL2817787 | 0.78 | APP (0.74) | SMN1; SMN2LMNATSHRCYP1A2CYP3A4 | |
| SCHEMBL12175936 | 0.78 | APP (0.74) | LMNATSHRHPGDACHEAPP | |
| SCHEMBL2256456 | 0.78 | EGFR (0.67) | CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL2395193 | 0.77 | APP (0.73) | SMN1; SMN2LMNATSHRCYP1A2CYP3A4 | |
| SCHEMBL2263166 | 0.76 | ACHE (0.65) | SMN1; SMN2ACHEAPPCTNNB1TCF7L2 | |
| SCHEMBL12176179 | 0.76 | APP (0.71) | LMNATSHRACHEAPPCTNNB1 | |
| SCHEMBL3126067 | 0.76 | APP (0.67) | LMNATSHRACHEAPPHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | claimed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | claimed |
| EP-1833482-A2 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | claimed |
| WO-2006074147-A2 | NITROGEN CONTAINING BICYCLIC COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1833482-A2 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006074147-A2 | NITROGEN CONTAINING BICYCLIC COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | SMN1; SMN2 1773/4885LMNA 1197/4885TSHR 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.